Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Rare Tumour × Irinotecan × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 192 Rectal Neoplasms 75 Colonic Neoplasms 68 Stomach Neoplasms 51 Pancreatic Neoplasms 41 Esophageal Neoplasms 35 Neoplasm Metastasis 34 Neoplasms 25 Lung Neoplasms 23 Small Cell Lung Carcinoma 18 Glioblastoma 18 Adenocarcinoma Of Esophagus 18 Glioma 16 Esophageal Squamous Cell Carcinoma 16 Carcinoma, Non-Small-Cell Lung 16 Neuroblastoma 15 Brain Neoplasms 14 Breast Neoplasms 13 Sarcoma 10 Gliosarcoma 10 Biliary Tract Neoplasms 10 Central Nervous System Neoplasms 8 Medulloblastoma 7 Astrocytoma 7 Adenocarcinoma 7 Recurrence 6 Oligodendroglioma 6 Locally Advanced Rectal Cancer 6 Colorectal Cancer Metastatic 6 Sarcoma, Ewing 5

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡